Overview of Meta-analysis of Lianhua Qingwen preparations in treatment of viral diseases.
10.19540/j.cnki.cjcmm.20220510.501
- Author:
Wei-Feng LI
1
;
Chan-Chan HU
2
;
Ya-Li DING
1
;
Bin YUAN
2
Author Information
1. Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210023, China Nanjing University of Chinese Medicine Nanjing 210023, China.
2. Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210023, China.
- Publication Type:Review
- Keywords:
Lianhua Qingwen preparations;
coronavirus disease 2019(COVID-19);
hand,foot and mouth disease(HFMD);
influenza;
overview of Meta-analysis;
virus infection
- MeSH:
Cough;
Drugs, Chinese Herbal/therapeutic use*;
Fatigue;
Fever/drug therapy*;
Humans;
Influenza, Human/drug therapy*;
Meta-Analysis as Topic;
Nonprescription Drugs/therapeutic use*;
Nucleic Acids/therapeutic use*;
Oseltamivir/therapeutic use*;
Ribavirin/therapeutic use*;
COVID-19 Drug Treatment
- From:
China Journal of Chinese Materia Medica
2022;47(16):4505-4516
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to obtain higher-level evidence by overviewing the Meta-analysis of Lianhua Qingwen preparations in the treatment of viral diseases including influenza, coronavirus disease 2019(COVID-19), and hand, foot and mouth disease(HFMD). CNKI, Wanfang, VIP, China Clinical Trial Registry(ChiCTR), PubMed, EMbase, Web of Science, and Cochrane Library were searched for the Meta-analysis about the treatment of viral diseases with Lianhua Qingwen preparations from the database establishment to April 1, 2022. After literature screening and data extraction, AMSTAR2 and the grading of recommendations assessment, development and evaluations(GRADE) system were used to assess the methodological quality and evidence quality, respectively, and then the efficacy and safety outcomes of Lianhua Qingwen preparations in the treatment of viral diseases were summarized. Thirteen Meta-analysis were finally included, three of which were rated as low grade by AMSTAR2 and ten as very low grade. A total of 75 outcome indicators were obtained, involving influenza, COVID-19, and HFMD. According to the GRADE scoring results, the 75 outcome indicators included 5(6.7%) high-level indicators, 18(24.0%) mediate-level indicators, 25(33.3%) low-level evidence indicators, and 27(36.0%) very low-level indicators.(1)In the treatment of influenza, Lianhua Qingwen preparations exhibited better clinical efficacy than other Chinese patent medicines and Ribavirin and had similar clinical efficacy compared with Oseltamivir. Lianhua Qingwen preparations were superior to other Chinese patent medicines, Oseltamivir, and Ribavirin in alleviating clinical symptoms. They showed no significant differences from Oseltamivir or conventional anti-influenza treatment in terms of the time to and rate of negative result of viral nucleic acid test.(2)In the treatment of COVID-19, Lianhua Qingwen preparation alone or combined with conventional treatment was superior to conventional treatment in terms of total effective rate, main symptom subsidence rate and time, fever clearance rate, duration of fever, time to fever clearance, cough subsidence rate, time to cough subsidence, fatigue subsidence rate, time to fatigue subsidence, myalgia subsidence rate, expectoration subsidence rate, chest tightness subsidence rate, etc. Lianhua Qingwen preparations no difference from conventional treatment in terms of subsiding sore throat, nausea, diarrhea, loss of appetite, headache, and dyspnea. In terms of chest CT improvement rate, rate of progression to severe case, cure time, and hospitalization time, Lianhua Qingwen alone or in combination with conventional treatment was superior to conventional treatment.(3)In the treatment of HFMD, Lianhua Qingwen Granules was superior to conventional treatment in terms of total effective rate, average fever clearance time, time to herpes subsidence, and time to negative result of viral nucleic acid test.(4)In terms of safety, Lianhua Qingwen preparations led to low incidence of adverse reactions, all of which were mild and disappeared after drug withdrawal. The available evidence suggests that in the treatment of influenza, COVID-19, and HFMD, Lianhua Qingwen preparations can relieve the clinical symptoms, shorten the hospitalization time, and improve the chest CT. They have therapeutic effect and good safety in the treatment of viral diseases. However, due to the low quality of available studies, more high-quality clinical trials are needed to support the above conclusions.
